The platform is not organized by specialty. It is organized around a kind of patient who appears in all of them: rare, complex, fast-moving, unresponsive to therapy, or simply unresolved after repeated evaluation.
Oncology
For refractory and difficult-to-treat disease, and for patients whose response to therapy is diverging from what was expected. The platform presents tumor burden and treatment response across the whole course of care, alongside the staging and survival measures a tumor board already works from, with the contributing encounters attached to any divergence it surfaces.
It also separates two situations that look identical in a chart: a therapy that is not working, and a therapy that is not reaching its target. The platform reads the patient’s response to the drug against the underlying course of the disease, which is what makes the two distinguishable at all. That distinction is frequently the difference between a line of treatment being abandoned and a dose or schedule being adjusted, and it is not one a chart review reliably makes.
Infectious disease
For complex, resistant and atypical presentations, and for treatment courses that are not achieving their intended effect. The platform tracks organism burden against the patient’s own clearance over time rather than at isolated points, and where the two diverge it presents the divergence together with the results behind it.
It also shows where the pressure of current therapy is visible in the record. Emerging resistance becomes a documented observation in front of the treating team while it is happening, not a conclusion reconstructed later.
Metabolic and inherited conditions
For presentations where routine chemistry stays within range while the patient’s trajectory deteriorates. This is the setting the platform was originally built for, and the one where conventional thresholds fail most predictably.
A patient with an attenuated physiological baseline can lose considerable ground without ever crossing a standard reference limit. Because the platform reads the direction and rate of change across encounters rather than the value at any single visit, that pattern becomes visible while it is still early. It also accounts for the social and environmental circumstances already documented in the record, and shows where a patient’s response to a drug is flattening rather than holding.
Rare and inherited conditions carry a second difficulty, described in the rare disease literature as the diagnostic odyssey. Published estimates place the interval between a first recorded symptom and a settled diagnosis at roughly five years, frequently involving seven or more specialists, with each assessment recorded separately and rarely read together. The platform reads those encounters as one connected sequence, broadens the differential on that basis, and presents the observations underlying every consideration so the treating clinician can examine the reasoning rather than accept it.
Neurology and psychiatry
For progressive and treatment-resistant conditions where the rate of change matters more than the status recorded at any single visit. The platform charts recognized severity instruments across the full course of care and shows where a treatment response is flattening, alongside the psychosocial factors already present in the chart.
For conditions assessed episodically and at long intervals, most of the information is in the interval rather than in the assessment. Two scores several months apart describe a slope that neither describes alone.
Hepatology, critical care and multi-system presentations
For complex presentations that fall between services, where no single specialty holds the whole picture and each holds a defensible part of it.
Multi-system disease is where the record is most fragmented and where the sequence of encounters carries more information than any individual result. The platform reads that sequence across services and presents what it shows, with every contributing encounter attached, which gives a consulting service something to work from other than a summary written by someone else.
Research, population health and one health
For evidence generation, preclinical work, population surveillance and veterinary applications. Cross-species work is handled on a species and breed basis, with dosing and pharmacogenomics specific to the animal rather than adapted from human assumptions.
Some conditions have no approved therapy. The platform maps untreated natural history and surfaces active trials the patient may be eligible for. The absence of a standard of care stops being the end of the conversation with a family.
Where the published evidence for a condition is thin, the platform says so on the finding itself rather than in a methods note somewhere else. Findings resting on direct evidence are distinguished from those resting on inference, so a clinician always knows which is which. Nothing is presented as better established than it is, which matters most in exactly the conditions where least is known.
Rheumatology and autoimmune disease
Patients on biologic therapy whose inflammatory markers drift while each individual result stays defensible. Reading those markers as a sequence shows loss of response developing, with the contributing results attached, at the point a clinician is considering whether the current agent is still the right one.
Preventative and longevity medicine
Separating the rate at which a patient is actually changing from the ordinary noise of repeated testing. The same trajectory reading that surfaces disease in an unresolved patient describes the pace of change in a well one, which is the question preventative programs are built around.
Five patterns, present in every specialty
Across all five patterns the platform behaves the same way. It is bounded by physiology and cannot return a result the body could not produce. The same record returns the same result every time, with every contributing observation attached.
The specialties above differ in almost every respect. The patients within them who remain unresolved do not. Five patterns recur, and the platform is built to recognize all five.
Rare conditions
Too uncommon for statistical methods to have learned from. The platform reasons from established medical knowledge rather than local case volume, so it contributes at a site that has never seen the condition.
Complex presentations
Multi-system pictures that fall between services rather than within one, where no single specialty holds the whole record.
High Avidity
Avidity is the measured rate at which a patient’s findings change across encounters. A patient can sit inside the reference interval at every visit and still be moving hard in one direction across eleven of them. Where avidity is high, late recognition costs years of function and therapy spent on the wrong target. The platform surfaces the trajectory with every contributing result attached. The clinician examines it and judges.
Non-response
Patients on high-cost therapy that is not working for them, often for months or years before anyone establishes it. The platform reconciles recorded response against expected response and presents the divergence, so treatment can be matched to the people it actually helps.
Treatment resistance
Refractory, repeatedly readmitted, or simply unresolved after many encounters with many clinicians. These patients have already survived several rounds of conventional evaluation, which is precisely why a conclusion they cannot interrogate is of no use to them.
Applying this in a specific setting
Institutions typically begin with one clinical service and one defined question. Briefings are conducted by the people who built the platform and are best attended by clinical leadership, the security team, and whoever is least inclined to believe any of it.